Novartis Pharmaceuticals Corporation
Open positions
Openings read from Novartis Pharmaceuticals Corporation’s own job board on Workday, last checked NOV 12, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Senior Engineer, MS&T - Technology TransferDurham · posted NOV 12, 2026
- BioProcess Engineer IDurham · posted NOV 12, 2026
- Dermatology Territory Account Specialist – Cherry Hill, Newark, PhiladelphiaField Sales (USA); Newark (New Jersey); Philadelphia (Pennsylvania); Cherry Hill (New Jersey) · posted NOV 12, 2026
- Automation Engineer III - Downstream/BufferDurham · posted NOV 12, 2026
- Financial Accounting & Reporting Specialist, Intercompany (m/f/d) – Fixed term contractBasel (City) · posted NOV 12, 2026
- • In-Vivo Translational Toxicology Scientist, Principal Scientist I or IICambridge (USA) · posted NOV 12, 2026
- Globalni GMP revizor ekspert za kakovost / Senior Global GMP Quality AuditorLjubljana · posted NOV 12, 2026
- Quality Manager, Third-Party ManagementSchaftenau · posted NOV 12, 2026
- Patient Experience & Activation AssociatePanama · posted NOV 12, 2026
- MS&T Lead, IsotopesIndianapolis · posted NOV 12, 2026
497 more on the company’s board
Supplier designations
Self-certified by the company in its SAM.gov registration
Terms of sale
DeliveryWe reserve the right to deduct 5% and 10% from the total invoice value in case of un-notified late delivery of 1 (one) and 2 (two) weeks respectively. 2.3. We reserve the right to…
2. Performance, Delivery: 2.1. The Items must conform to our specifications, failing which, the goods will be rejected and the rejected material will not be returned. Any cost related to releasing, receiving, handling and destruction etc. (including but not limited to clearing charges and customs fees etc.) of the rejected materials shall be on the account of the supplier and the amount shall be reimbursed by the supplier by issuing debit note against Novartis (Bangladesh) Limited. 2.2. The time of delivery indicated in the purchase order shall be binding. If there is any foreseeable delay in the delivery of a product or service, or non-conformance in quality, we must be informed immediately in writing. We reserve the right to deduct 5% and 10% from the total invoice value in case of un-notified late delivery of 1 (one) and 2 (two) weeks respectively. 2.3. We reserve the right to refuse to accept delivery if the supply is late by more than 2 (two) weeks from the delivery date mentioned on this Purchase Order. However, supply may be conditionally accepted with a deduction up to 50% on total invoice value. 2.4. If delay in delivery is anticipated by the supplier because of any unavoidable and/or unforeseen event (Force Majeure), the supplier must notify the likelihood or actual occurrence of that event to the requestor of this Purchase Order within 1 (one) week from the date of this Purchase Order and/or from the date of occurrence of the event, whichever is earlier. The suppli
“Performance, Delivery” · Page No: 1 of 2 · open the document (PDF)
WarrantyTitle, Confidentiality, Warranty: 7.1. Title to the goods shall be transferred to us unconditionally and regardless of payment of the purchase price. 7.2. We retain title…
7. Title, Confidentiality, Warranty: 7.1. Title to the goods shall be transferred to us unconditionally and regardless of payment of the purchase price. 7.2. We retain title, intellectual property right, or copyright to all orders, all documents, samples or materials provided to the supplier. 7.3. The supplier agrees to keep confidential the terms and conditions of the purchase order and all documents, samples and other information (hereinafter jointly referred to as "Information") provided for that purpose even after the contract has been completed and to use such Information and documents only for the purpose of carrying out the purchase order. The aforementioned obligations shall not apply to Information which is publicly accessible or which was rightfully known to the supplier prior to the receipt of such Information without any confidentiality obligation. After completing the inquiries or handling the purchase orders, the supplier must promptly return such Information to us and destroy any copies thereof, upon our request. 7.4. The supplier warrants that the products are free from any defects and shall in particular meet all agreed specifications and standards. The supplier warrants that the import, storage, sale and conventional use of the products shall not infringe any third party’s patent or other intellectual property rights. Insofar as the products ordered by us are medicinal, healthcare, cosmetic, nutrition or dietary supplement products or serve to manufacture su
“Title, Confidentiality, Warranty” · Page No: 1 of 2 · open the document (PDF)
From Novartis Pharmaceuticals Corporation’s own terms and conditions of sale · read October 21, 2026 · not verified by FactoryRegistry
Patents
19 US patents granted 1998–2023, 4 of them in the five years to SEP 2025.
- Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsUS 11,642,329 · granted MAY 9, 2023
- Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsUS 11,096,918 · granted AUG 24, 2021
- Crystalline pharmaceutical and methods of preparation and use thereofUS 11,028,077 · granted JUN 8, 2021
- LFA-1 inhibitor and methods of preparation and polymorph thereofUS 10,906,892 · granted FEB 2, 2021
- Processes for producing NEP inhibitors or prodrugs thereofUS 9,061,973 · granted JUN 23, 2015
Newest 5 shown · Granted to Novartis Pharmaceuticals Corporation · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plants
7 FACILITIES| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | San Carlos | CA | — | REPORTED CLOSED |
| Novartis Pharmaceuticals Corporation | East Hanover | NJ | — | UNVERIFIED |
| Novartis Pharmaceuticals CORP | East Hanover | NJ | — | LIKELY ACTIVE |
| Novartis Pharmaceuticals Corporation | East Hanover | NJ | 500+ | ACTIVE |
| Novartis Pharmaceuticals CORP | Morris Plains | NJ | 500+ | LIKELY ACTIVE |
| Novartis Pharmaceuticals CORP. | Summit | NJ | — | UNVERIFIED |
| Novartis Pharmaceuticals CORP @ Dhl Supply Chain Distr Ctr | Mechanicsburg | PA | — | UNVERIFIED |
WARN Act notices
- Plant closing notice effective JUN 27, 2025 · 34 employees · San Diego County, CA
- Plant closing notice effective JUN 27, 2025 · 1 employees · San Diego County, CA
- Plant closing notice effective SEP 6, 2024 · 29 employees · San Diego County, CA
- WARN notice effective NOV 24, 2023 · 103 employees · Hanover, NJ
- Plant closing notice effective OCT 1, 2019 · 102 employees · Novartis Pharmaceuticals Corporation — this notice sets that plant’s status
- Layoff notice effective JAN 31, 2017 · 7 employees · Novartis Pharmaceuticals Corporation
- Layoff notice effective JAN 31, 2017 · 75 employees · Novartis Pharmaceuticals Corporation
Filed with the state under the federal WARN Act · WARN Act notices feed, CC BY 4.0
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


